ATE406178T1 - Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen - Google Patents
Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellenInfo
- Publication number
- ATE406178T1 ATE406178T1 AT98960189T AT98960189T ATE406178T1 AT E406178 T1 ATE406178 T1 AT E406178T1 AT 98960189 T AT98960189 T AT 98960189T AT 98960189 T AT98960189 T AT 98960189T AT E406178 T1 ATE406178 T1 AT E406178T1
- Authority
- AT
- Austria
- Prior art keywords
- presenting cells
- depupperation
- immunoreactivity
- antigen
- inhibition
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title abstract 3
- 230000005764 inhibitory process Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 230000008827 biological function Effects 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6519897P | 1997-11-12 | 1997-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE406178T1 true ATE406178T1 (de) | 2008-09-15 |
Family
ID=22061000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98960189T ATE406178T1 (de) | 1997-11-12 | 1998-11-12 | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen |
Country Status (6)
Country | Link |
---|---|
US (1) | US7288255B1 (de) |
EP (1) | EP1028754B1 (de) |
AT (1) | ATE406178T1 (de) |
AU (1) | AU754764B2 (de) |
DE (1) | DE69839943D1 (de) |
WO (1) | WO1999024078A1 (de) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2324199A1 (en) | 2000-10-25 | 2002-04-25 | Vasogen Ireland Limited | Chronic lymphocytic leukemia treatment |
AU2002218019A1 (en) * | 2000-11-03 | 2002-05-15 | Nexell Therapeutics Inc. | Methods for depleting and isolating alloreactive and antigen-reactive t cells from hematopoietic donor cells |
BR112017021536A2 (pt) | 2015-04-06 | 2018-07-03 | Harvard College | composições e métodos para o condicionamento não mieloablativo |
EA039364B1 (ru) * | 2015-10-09 | 2022-01-18 | Президент Энд Феллоус Оф Гарвард Колледж | Композиции и способы для немиелоаблативного кондиционирования |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
EP3765044A4 (de) | 2018-03-12 | 2021-12-08 | Medeor Therapeutics, Inc. | Verfahren zur behandlung von nichtkanzerösen erkrankungen unter verwendung von hämatopoetischen zellen |
US10842821B2 (en) | 2018-04-05 | 2020-11-24 | Medeor Therapeutics, Inc. | Cellular compositions derived from prior organ donors and methods of manufacture and use thereof |
US10881692B2 (en) | 2018-04-05 | 2021-01-05 | Medeor Therapeutics, Inc. | Compositions for establishing mixed chimerism and methods of manufacture thereof |
US11435350B2 (en) | 2018-09-18 | 2022-09-06 | Medeor Therapeutics, Inc. | Methods of analysis of blood from deceased donors |
US11813376B2 (en) | 2018-09-18 | 2023-11-14 | Medeor Therapeutics, Inc. | Cellular compositions derived from deceased donors to promote graft tolerance and manufacture and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5239062A (en) * | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
GB9117522D0 (en) * | 1991-08-14 | 1991-10-02 | Medical Res Council | Ligands for dendritic cells, their uses and production |
-
1998
- 1998-11-12 DE DE69839943T patent/DE69839943D1/de not_active Expired - Fee Related
- 1998-11-12 WO PCT/US1998/024183 patent/WO1999024078A1/en active IP Right Grant
- 1998-11-12 EP EP98960189A patent/EP1028754B1/de not_active Expired - Lifetime
- 1998-11-12 AU AU15849/99A patent/AU754764B2/en not_active Ceased
- 1998-11-12 AT AT98960189T patent/ATE406178T1/de not_active IP Right Cessation
-
2000
- 2000-05-11 US US09/568,834 patent/US7288255B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1028754A1 (de) | 2000-08-23 |
AU754764B2 (en) | 2002-11-21 |
US7288255B1 (en) | 2007-10-30 |
DE69839943D1 (de) | 2008-10-09 |
AU1584999A (en) | 1999-05-31 |
EP1028754B1 (de) | 2008-08-27 |
EP1028754A4 (de) | 2002-11-27 |
WO1999024078A1 (en) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE326239T1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
PT1032662E (pt) | Metodos e composicoes para imunomodulacao. | |
IL189629A0 (en) | Compositions containing human ctla-4 antibodies | |
NO982062D0 (no) | Humaniserte antistoff mot humant gp39, sammensetninger inneholdende dette, samt terapeutisk anvendelse derav | |
PL328858A1 (en) | Immunogenous peptides | |
BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
DE69435303D1 (de) | Er behandlung von krankheiten bei denen eine cytok | |
SE8902532L (sv) | Bestaemning av plasmaproteiner | |
ATE406178T1 (de) | Verhinderung von immunreaktivität durch verarmung oder inhibition von antigen-präsentierenden zellen | |
AR016295A1 (es) | Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme | |
DE69732709D1 (de) | Expressionsblockierung von virulenten faktoren in s. aureus | |
PT845998E (pt) | Medicamentos para imunoterapia contendo anticorpos que reconhecem de forma especifica o antigenio mhcii de um paciente a ser tratado | |
DE69426767D1 (de) | Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen. | |
HUP0001458A2 (hu) | Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása | |
NO963487L (no) | Isolerte, tyrosinaseavledete peptider, samt anvendelser derav | |
HK1071079A1 (en) | Use of soluble fgl2 as an immunosuppressant | |
WO2004047757A3 (en) | Diagnosing and treating hematopoietic cancers | |
DE69534633D1 (de) | Implantat und vektor zur behandlung von erworbenen krankheiten | |
PT723552E (pt) | Oligopeptidos derivados de fragmentos de proteina reactiva c | |
DE69636041D1 (de) | Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen | |
ID23184A (id) | Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi | |
WO1998051782A3 (en) | Human 3-hydroxyisobutyryl-coenzyme a hydrolase | |
ATE435284T1 (de) | Zusammensetzungen und verfahren zur therapie und diagnose von lungenkrebs | |
WO1999050671A3 (en) | Toso as a target for drug screening | |
DE50207168D1 (de) | Kombinationspräparat zur Therapie von immunologischen Erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |